Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.
bronchial asthma
chronic rhinosinusitis with nasal polyposis
dupilumab
egpa
hyper-eosinophilia
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
22
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Eosinophilic granulomatosis with polyangiitis (EGPA) refers to systemic vasculitis in patients with bronchial asthma and eosinophilic rhinosinusitis. Dupilumab has been approved for the treatment of asthma, eosinophilic rhinosinusitis, and atopic dermatitis. A man in his 50s with a history of asthma and eosinophilic rhinosinusitis with nasal polyposis developed high fever and dyspnea while undergoing dupilumab treatment. Laboratory examinations identified hypereosinophilia. Chest radiography and computed tomography revealed right-sided tracheal dislocation, extensive consolidation, and ground-glass opacities with traction bronchiectasis. Evidence of interstitial pneumonia, eosinophilia, and increased eosinophil counts in the bronchoalveolar lavage fluid was observed. We diagnosed the patient with EGPA and administered corticosteroids, which improved his symptoms and radiographic signs. Although the relationship between EGPA and dupilumab treatment is unclear, EGPA may have been exacerbated by dupilumab in this case. Therefore, when administering dupilumab to patients with partial symptoms of EGPA, care should be taken to monitor for adverse symptom development and exacerbation.
Identifiants
pubmed: 35747049
doi: 10.7759/cureus.25218
pmc: PMC9213259
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e25218Informations de copyright
Copyright © 2022, Tanaka et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Rheum Dis. 2007 Feb;66(2):222-7
pubmed: 16901958
Ther Clin Risk Manag. 2017 Sep 01;13:1139-1149
pubmed: 28979129
Lancet. 2019 Nov 2;394(10209):1638-1650
pubmed: 31543428
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
J Clin Med. 2020 Nov 30;9(12):
pubmed: 33265990
Expert Rev Clin Immunol. 2020 Jan;16(1):51-61
pubmed: 31762336
N Engl J Med. 1998 May 28;338(22):1592-600
pubmed: 9603798
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2913-2915
pubmed: 33676050
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Clin Exp Allergy. 2020 Feb;50(2):267-270
pubmed: 31621112